Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO

Inclusion Criteria: * Patients must have completed the core study assessments at month 6 of study CRFB002EDE17 or CRFB002EDE18, respectively Exclusion Criteria: * Patients who experienced an uncontrollable rise in IOP during the core study CRFB002EDE17 respectively CRFB002EDE18, i.e. IOP could not be decreased to a stable level of \< 25mmHg. * Use of other investigational drugs * Current use or likely need of systemic medications known to be toxic to the lens, retina or optic nerve * History of hypersensitivity to Ranibizumab or Ozurdex or any component of the ranibizumab respectively Ozurdey formulation * Any type of advanced, severe or unstable disease or its treatment, that could interfere with evaluations or put the patient at special risk * Women * who were pregnant or breast feeding (pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>5 mIU/mL) * who were menstruating and capable of becoming pregnant\* and not practicing a medically approved method of contraception (Pearl Index \<1\*\*)\*\*\* during and up to at least 4 weeks after the end of treatment. A negative pregnancy test (serum) for all women and for girls entering menarche was required with sufficient lead time before randomization * definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \>40 mIU/mL or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy * examples of particularly reliable methods with Pearl Index (PI) \<1, according to guidelines of "Deutsche Gesellschaft für Gynäkologie und Geburtshilfe": * Combination pill with estrogen and gestagen (no mini-pill, PI=0.1-0.9) * Vaginal ring (NuvaRing®, PI=0.65 uncorr.; 0.4 corr.) * Contraceptive patch (EVRA®, PI= 0.72 uncorr.; 0.9 corr.) * Estrogen-free ovulation inhibitors (Cerazette®, PI=0.14) * Progestin-containing contraceptives (Implanon®, PI=0-0.08) * Injectable 3-month depot progestins (PI=0.3-1.4; 0.88 corr.) * Intra-uterine progestin device (Mirena®, PI=0.16)